283 related articles for article (PubMed ID: 35039078)
21. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
22. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
23. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
24. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
[TBL] [Abstract][Full Text] [Related]
25. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
26. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
27. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.
Oh DJ; Nam JH; Lee HS; Moon YR; Lim YJ
Korean J Intern Med; 2024 Mar; 39(2):228-237. PubMed ID: 38321358
[TBL] [Abstract][Full Text] [Related]
28. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
29. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
30. A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients.
Fleishman NR; Richardson T; Attard TM
Curr Med Res Opin; 2022 Apr; 38(4):565-570. PubMed ID: 35112645
[TBL] [Abstract][Full Text] [Related]
31. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease.
Benson VS; Müllerová H; Vestbo J; Wedzicha JA; Patel A; Hurst JR;
Respir Med; 2015 Sep; 109(9):1147-54. PubMed ID: 26166017
[TBL] [Abstract][Full Text] [Related]
32. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Brusselaers N; Sadr-Azodi O; Engstrand L
J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
[TBL] [Abstract][Full Text] [Related]
33. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
34. Effect of Gastric Acid Suppressants on Response to a Physical Activity Intervention and Major Mobility Disability in Older Adults: Results from the Lifestyle Interventions for Elders (LIFE) Study.
Squires PJ; Pahor M; Manini TM; Brown JD
Pharmacotherapy; 2019 Aug; 39(8):816-826. PubMed ID: 31230397
[TBL] [Abstract][Full Text] [Related]
35. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.
McCaleb RV; Gandhi AS; Clark SM; Clemmons AB
Ann Pharmacother; 2016 Jul; 50(7):541-7. PubMed ID: 27091869
[TBL] [Abstract][Full Text] [Related]
37. Choice of Acid Suppressant Therapy and Long-Term Graft Outcomes After Kidney Transplantation.
January SE; Progar K; Nesselhauf NM; Hagopian JC; Malone AF
Pharmacotherapy; 2020 Nov; 40(11):1082-1088. PubMed ID: 33037663
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants.
Green DS; Abdel-Latif ME; Jones LJ; Lui K; Osborn DA
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD011785. PubMed ID: 31265739
[TBL] [Abstract][Full Text] [Related]
39. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
40. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
